erlotinib HCl

DRUG5 trials

Sponsors

Genentech, Inc.

Conditions

Non-Small Cell Lung CancerNon-Squamous Non-Small Cell Lung Cancer, Solid Cancers

Phase 1

A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

CompletedNCT00453362

Genentech, Inc.Non-Small Cell Lung Cancer

Start: 2006-12-31End: 2010-04-23Updated: 2017-03-31

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

CompletedNCT00975182

Genentech, Inc.Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers

Start: 2009-09-30End: 2014-09-30Updated: 2016-11-02

Phase 2

A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)

CompletedNCT00854308

Genentech, Inc.Non-Small Cell Lung Cancer

Start: 2009-04-30End: 2012-01-31Updated: 2017-03-31

Phase 3

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

CompletedNCT00130728

Genentech, Inc.Non-Small Cell Lung Cancer

Start: 2005-06-08End: 2019-12-23Updated: 2021-01-14

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

CompletedNCT00257608

Genentech, Inc.Non-Small Cell Lung Cancer

Start: 2006-01-31End: 2014-11-30Updated: 2016-04-18

Related Papers

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

2011-05-01307 citations